Robert Adair, MD
Internal Medicine · New York, NYNPI 1457467862
Payments from drug & device makers
Across 242 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$640
- Novo Nordisk$449
- Lilly USA, LLC$388
- AbbVie$383
- Boehringer Ingelheim$329
- Johnson & Johnson$296
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,238100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $640 |
| Novo Nordisk | 27 | $449 |
| Lilly USA, LLC | 24 | $388 |
| AbbVie(2 entities) | 22 | $383 |
| Boehringer Ingelheim | 12 | $329 |
| Johnson & Johnson | 19 | $296 |
| Almatica Pharma LLC | 17 | $278 |
| Amgen | 13 | $196 |
| GSK | 9 | $165 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $154 |
| Pfizer | 9 | $145 |
| Bayer | 7 | $134 |
| Amarin Pharma, Inc. | 5 | $91 |
| Phathom Pharmaceuticals, Inc. | 4 | $66 |
| Merck | 5 | $65 |
| Astellas Pharma US Inc | 3 | $61 |
| Gilead | 2 | $46 |
| Exact Sciences | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Novartis | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$125
How this compares
$4,259 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $130,433 |
| JardianceEmpagliflozin | 72 | $94,151 |
| EliquisApixaban | 42 | $54,872 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $51,304 |
| JanuviaSitagliptin Phosphate | 40 | $51,138 |
| RybelsusSemaglutide | 27 | $42,708 |
| XareltoRivaroxaban | 26 | $36,402 |
| TrulicityDulaglutide | 15 | $32,835 |
| TradjentaLinagliptin | 26 | $29,232 |
| LinzessLinaclotide | 30 | $24,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $23,810 |
| MyrbetriqMirabegron | 16 | $15,707 |
| KerendiaFinerenone | 11 | $6,785 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,422 |
| Atorvastatin Calcium | 479 | $5,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $449 | $173,141108 claims |
| Boehringer IngelheimJardiance, Tradjenta | $329 | $123,38298 claims |
| MerckJanumet, Januvia | $65 | $102,44284 claims |
| PfizerEliquis | $145 | $54,87242 claims |
| Johnson & JohnsonXarelto | $296 | $36,40226 claims |
| Lilly USA, LLCTrulicity | $388 | $32,83515 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $165 | $32,40358 claims |
| AbbVieLinzess | $383 | $24,88430 claims |
| Astellas Pharma US IncMyrbetriq | $61 | $15,70716 claims |
| BayerKerendia | $134 | $6,78511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.